PF-1355 is a selective 2-thiouracil mechanism-based MPO inhibitor, used for treatment of vasculitic diseases.
规格 | 价格 | 会员价 | 库存 | 数量 | |||
---|---|---|---|---|---|---|---|
{[ item.pr_size ]} |
{[ getRatePrice(item.pr_rmb, 1,1) ]} {[ getRatePrice(item.pr_rmb_sale, 1,1) ]} {[ suihuo_tips(item.pr_am, item.pr_size) ]} |
{[ getRatePrice(item.pr_rmb, 1,1) ]} {[ getRatePrice(item.pr_rmb,item.pr_rate,1) ]} {[ suihuo_tips(item.pr_am, item.pr_size) ]} |
{[ getRatePrice(item.pr_rmb, 1,1) ]}{[ suihuo_tips(item.pr_am, item.pr_size) ]} | {[ getRatePrice(item.pr_rmb_sale, 1,1) ]} {[ getRatePrice(item.pr_rmb,item.pr_rate,item.mem_rate) ]} {[ getRatePrice(item.pr_rmb,1,item.mem_rate) ]} | 现货 | 咨询 | - + |
快速发货 顺丰冷链运输,1-2 天到达
品质保证
技术支持
免费溶解
描述 | PF-1355 demonstrates a dose-dependent inhibition of MPO activity in human neutrophils activated by phorbol ester, as indicated by taurine chlorination with an EC50 of 1.47 μM, and in human blood treated with LPS, as shown by the measurement of remaining MPO activity with an EC50 of 2.03 μM[1]. |
Animal study | When administered orally, PF-1355 decreases plasma MPO activity, vascular swelling, neutrophil infiltration, and increases circulating cytokines. In a model of what used to be called Goodpasture disease, now referred to as anti-glomerular basement membrane disease, PF-1355 completely prevents albuminuria and chronic kidney dysfunction[1]. |
计算器 | ||||
存储液制备 | 1mg | 5mg | 10mg | |
1 mM 5 mM 10 mM |
3.11mL 0.62mL 0.31mL |
15.56mL 3.11mL 1.56mL |
31.12mL 6.22mL 3.11mL |
CAS号 | 1435467-38-1 |
分子式 | C14H15N3O4S |
分子量 | 321.352 |
别名 | PF-06281355 |
运输 | 蓝冰 |
存储条件 |
液体 -20°C:3-6个月-80°C:12个月 粉末 Sealed in dry,Room Temperature |
溶解度 |
DMSO: 50 mg/mL(155.59 mM),配合低频超声助溶,注意:DMSO长时间开封后,会吸水并导致溶解能力下降,请避免使用长期开封的DMSO |
动物实验配方 |